Tehran University of Medical Sciences Journal of Pharmacoeconomics and Pharmaceutical Management 2383-4498 7 3/4 2021 12 11 100 112 Abdulganiyu Giwa Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmaceutical Sciences, University of Ilorin, Ilorin, Nigeria. Carene Sabum Specialist Hospital, Jalingo, Nigeria. Halima Giwa Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmaceutical Sciences, University of Ilorin, Ilorin, Nigeria. Muslim Jamiu Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmaceutical Sciences, University of Ilorin, Ilorin, Nigeria. 2021 03 18 2021 09 20 Background: This study aimed to assess Health-Related Quality of Life (HRQoL) in cancer patients receiving chemotherapy in Specialist Hospital, Jalingo, North-Eastern Nigeria, in 2015. Methods: A cross-sectional study was conducted on 218 cancer patients selected by systematic random sampling method. The study data were collected using a modified European Organization for Research and Treatment of Cancer QoL Questionnaire (EORTC QLQ-C30 v. 3). Results: Out of the 218 participants, 42(18.8%) had between 1 to 4 chemotherapy cycles, while 86(39.4%) had 5 to 8 cycles and the remaining 91(41.7%) had 9 to 12 chemotherapy cycles. There was a significant relationship between HRQoL and the number of chemotherapy cycles received. Conclusion: Encouraging cancer patients to complete a chemotherapy course plays an essential role in the treatment outcome and the HRQoL in cancer patients undergoing chemotherapy.   https://jppm.tums.ac.ir/index.php/jppm/article/view/161 https://jppm.tums.ac.ir/index.php/jppm/article/download/161/69